Prosecution Insights
Last updated: July 17, 2026
Application No. 18/832,631

COPOLYMER AND COSMETIC COMPOSITION CONTAINING SAID COPOLYMER

Non-Final OA §102§103§112
Filed
Jul 24, 2024
Priority
Jan 25, 2022 — JP 2022-009220 +1 more
Examiner
CHEN, PO-CHIH
Art Unit
Tech Center
Assignee
Adeka Corporation
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
559 granted / 753 resolved
+14.2% vs TC avg
Moderate +14% lift
Without
With
+14.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
55 currently pending
Career history
801
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
61.8%
+21.8% vs TC avg
§102
15.0%
-25.0% vs TC avg
§112
20.8%
-19.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 753 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAIL ACTION This office action is a response to a 371 application filed -----7/24/2024 which is a national stage application of PCT/JP2023/001028 filed 1/16/2023, which claims foreign priority to JP2022-009220 filed 1/25/2022. As filed, claims 1-6 are pending. Information Disclosure Statement The information disclosure statement (IDS) submitted on 12/5/2025 and 7/24/2024 has been considered by the Examiner. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Claim Rejections - 35 USC § 112 fourth paragraph The following is a quotation of the fourth paragraph of 35 U.S.C. § 112: Subject to the following paragraph [concerning multiple dependent claims], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers (emphasis added). Claim 2 is rejected under the fourth paragraph of 35 U.S.C. § 112 and under 37 CFR § 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Regarding claim 2, the claim is dependent upon claim 1. The subject matter in claim 1 is drawn to a copolymer in a product by process construction. The subject matter in claim 2 is drawn to a limited embodiment of the copolymer. The scope of claim 2 is broader than scope of claim 1 because claim 2 uses “comprises” language, which is open-ended, while claim 1 does not use open-ended language. Because the scope of claim 2 is broader than claim 1, the claim failed to further limit the subject matter thereof, and fail to comply with the formal requirements set forth in the fourth paragraph of 35 U.S.C § 112. The Examiner suggests that the claims be amended in a manner such that the scope of claim 2 is commensurate with the scope of claim 1. Claim Interpretation The Examiner finds the claim construction of claim 1 as a product by process limitation. In other words, the patentability of the instantly claimed copolymer is based on the copolymer itself, and not its method of preparation. Since dependent claims 2 and 3 are drawn to a limited embodiment of the abovementioned method of preparation, the patentability of claims 2 and 3 remained on the copolymer itself. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-6 are rejected under 35 U.S.C. 103 as being obvious over Foreign Patent Application Publication No. WO2021/182500 (see IDS filed 7/24/2024) and using U.S. Patent Application Publication No. 2023/0108458 as its English equivalent, hereinafter Miyazono. The applied reference has a common assignee/inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 103 might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C.102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B); or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. See generally MPEP § 717.02. Regarding claims 1-6: Determining the scope and contents of the prior art: Miyazono, for instance, teaches a copolymer made of polyglyceryl-2 diisostearate (which is commonly known to be a plant-derived emulsifier, wherein instant variable R1 is C17 alkyl; instant variables X1 and X2 are H; instant variable X3 is -C(=O)R2; and instant variable R2 is C17 alkyl) and isophorone diisocyanate (IPDI) or cosmetic composition thereof, wherein the weight-average molecular weight of the copolymer can range from 2000 to 10000, and the content of the abovementioned copolymer can range from 0.01 mass% to 20 mass% In addition, claims 2 and 3 are drawn to limitations further limiting the preparation process of the instant copolymer, which are not given patentable weight because the patentability of the claims is on the copolymer itself, and not its process of preparation. PNG media_image1.png 478 666 media_image1.png Greyscale (paragraph 0017) PNG media_image2.png 474 686 media_image2.png Greyscale (paragraph 0088) PNG media_image3.png 274 664 media_image3.png Greyscale (paragraph 0054) PNG media_image4.png 332 660 media_image4.png Greyscale (paragraph 0057) Ascertaining of the difference between the prior art and the claim at issue: Miyazono, for instance, did not explicitly teach the weight-average molecular weight of the copolymer is from 3,500 to 100,000 or from 5,000 to 40,000. Finding of prima facie obviousness --- rationale and motivation: The Examiner, according to the guidance in MPEP 2144.05(I)-(II), finds that a prima facie case of obviousness exists where the instantly claimed range of the weight-average molecular weight overlapped with the prior art. In addition, the Examiner does not find the abovementioned weight-average molecular weight of the copolymer as result-effective variable because the Applicant fails to demonstrate this parameter to impart any unexpected or novel aspect to the instant copolymer (i.e. no comparative example). “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). See MPEP 2144.05. Accordingly, this parameter is viewed as routine experimentation to optimize the instant copolymer, and not a patentable distinction. Conclusion Claims 1-6 are rejected. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jul 24, 2024
Application Filed
Jun 26, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678423
THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AND COMPOSITION FOR TREATMENT
7y 0m to grant Granted Jul 14, 2026
Patent 12668573
Linker, Antibody-Drug Conjugate Including Same and Use Thereof
5y 4m to grant Granted Jun 30, 2026
Patent 12653787
A PHARMACEUTICAL ORAL DOSAGE FORM OF Q203
4y 0m to grant Granted Jun 16, 2026
Patent 12655114
IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
3y 2m to grant Granted Jun 16, 2026
Patent 12643916
PROBE RELATED REAGENTS AND METHODS
2y 4m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.5%)
2y 4m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 753 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month